Kopra Bio

Cancer cures via viral immunotherapy

San Francisco, California, US

Kopra Bio is a biotechnology company developing immunotherapies for cancer, specifically for solid tumors, by using genetically engineered viruses that stimulate the immune system.

Shareable draft

Check out Kopra Bio on @MedStartr Today Kopra Bio is a biotechnology company developing immunotherapies for cancer, specifically for solid tumors, by using genetically engineered viruses that stimulate the immune system. #MentalBehavioralHealth #CancerOncology #DrugDiscoveryDevelopment #MedMo #MedStartrVentures

https://www.medstartr.ai/s/5wqWmqxh8Yg

Get Involved in Kopra Bio

How We Help

Problem Statement

Current cancer treatments have limited success rates in solid tumors and often target mutations individually. Kopra Bio is developing a therapy that teaches the immune system to kill cancer cells, addressing these limitations.

Core Technology

Genetically engineered viruses

Key Differentiators

Leverages genetically engineered viruses that selectively infect and spread throughout tumors.; Hijacks cancer cells to produce immune signals, recruiting T cells to kill the cancer.; Aims to cure cancer while also eliminating metastasis and recurrence.

Clinical Focus

Immunotherapy

Company Info

Business Model: B2B
Total Funding: Only accessible to MedStartr community members. Join now
Only accessible to MedStartr community members.
Join now
Website: kopra.bio

Disease Areas

Mental Health Cancer & Oncology

Technologies

Viral ImmunotherapyT-Cell Recruitment

Clinical & IP

🔬

Clinical Validation

Preclinical: 90% long-term survival in glioblastoma mouse models vs 0% control; Pre-IND stage; QB3 proof-of-concept award for breast, ovarian, colon cancer studies

🌐Website

MedStartr Engagement Score

The MedStartr Index is a reflection of how the crowds that come to MedStartr everyday to find healthcare innovations reacted. Calculated by our AI agent Fyggy based on algorithms we have been building since 2012 and over 100 different factors, the math is proprietary and complex. Suffice to say, it has been found to be highly correlative with early stage company growth. What you see here is the public version. To learn more or to get deeper access to our predictive data on startup success for your fund or company, click here.

Comments

Comments from new members are shown once the company's team has approved them. Please follow the community rules.

Be the first to comment.

What do you think of Kopra Bio?

A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.

Clinical Benefit Potential

The potential for a project to have a large and significant impact on medical care, treatment, or prevention.

Feasibility

The likelihood that this will provide benefit for patients / care givers and that the founders can execute on their vision and plan.

Innovativeness

The distinguishing features, concept, or technology that differentiates the entry compared to others that already exist and are in widespread use.

Fundability

The reviewers' beliefs that the idea is fundable or can make it to sustainability without outside investment.

Scalability

Some great ideas are destined to failure because they are too complex or too expensive. The reviewer should consider the likelihood that a project as explained, or perhaps with some tweaks, could possibly become a worldwide solution within a reasonable time frame.

Presentation Quality

How well the team presented the idea.

Submit anonymously — my name won't be shown to the team or on this profile

Your scores and comments are shown with your review on this company's profile.